Phenotypic behavior of C2C12 myoblasts upon expression of the dystrophy-related caveolin-3 P104L and TFT mutants

FEBS Letters

Volumn 581, Issue 26, 2007, Pages 5099-5104

  Fanzani, Alessandro ^a   Stoppani, Elena ^a   Gualandi, Laura ^a   Giuliani, Roberta ^a   Galbiati, Ferruccio ^b   Rossi, Stefania ^a   Fra, Anna ^a   Preti, Augusto ^a   Marchesini, Sergio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

AKT; Atrogin; Caveolin 3; Dystrophy; Follistatin; IL 4; Murf 1; NFATC2

Indexed keywords

ATROGIN; CAVEOLIN 3; FOLLISTATIN; INTERLEUKIN 4; MUTANT PROTEIN; PROTEIN KINASE B; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CAVEOLA; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENETIC TRANSFECTION; LIMB GIRDLE MUSCULAR DYSTROPHY; MOUSE; MUSCLE ATROPHY; MUTATION; MYOBLAST; MYOTUBE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CAVEOLIN 3; CELL DIFFERENTIATION; HUMANS; MICE; MUSCLE PROTEINS; MUTATION; MYOBLASTS; PHENOTYPE; SKP CULLIN F-BOX PROTEIN LIGASES; UBIQUITIN-PROTEIN LIGASES;

EID: 35348903938     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2007.09.055     Document Type: Article

References (24)

1. Song K.S., Scherer P.E., Tang Z., Okamoto T., Li S., Chafel M., Chu C., Kohtz D.S., and Lisanti M.P. Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J. Biol. Chem. 271 (1996) 15160-15165
2. Hnasko R., and Lisanti M.P. The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol. Interv. 3 (2003) 8445-8464 (Review)
3. Woodman S.E., Sotgia F., Galbiati F., Minetti C., and Lisanti M.P. Caveolinopathies: mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases. Neurology 62 (2004) 538-543 (Review)
4. Galbiati F., Volonte D., Engelman J.A., Scherer P.E., and Lisanti M.P. Targeted down-regulation of caveolin-3 is sufficient to inhibit myotube formation in differentiating C2C12 myoblasts. Transient activation of p38 mitogen-activated protein kinase is required for induction of caveolin-3 expression and subsequent myotube formation. J. Biol. Chem. 274 (1999) 30315-30321
5. Fanzani A., Musaro A., Stoppani E., Giuliani R., Colombo F., Preti A., and Marchesini S. Hypertrophy and atrophy inversely regulate Caveolin-3 expression in myoblasts. Biochem. Biophys. Res. Commun. 357 (2007) 314-318
6. Minetti C., Sotgia F., Bruno C., Scartezzini P., Broda P., Bado M., Masetti E., Mazzocco P., Egeo A., Donati M.A., Volonté D., Galbiati F., Cordone G., Bricarelli F.D., Lisanti M.P., and Zara F. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat. Genet. 18 (1998) 365-368
7. Galbiati F., Volonte D., Minetti C., Bregman D.B., and Lisanti M.P. Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation. J. Biol. Chem. 275 (2000) 37702-37711
8. Sunada Y., Ohi H., Hase A., Ohi H., Hosono T., Arata S., Higuchi S., Matsumura K., and Shimizu T. Transgenic mice expressing mutant caveolin-3 show severe myopathy associated with increased nNOS activity. Hum. Mol. Genet. 10 (2001) 173-178
9. Ohsawa Y., Hagiwara H., Nakatani M., Yasue A., Moriyama K., Murakami T., Tsuchida K., Noji S., and Sunada Y. Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition. J. Clin. Invest. 116 (2006) 2924-2934
10. Nixon S.J., Wegner J., Ferguson C., Mery P.F., Hancock J.F., Currie P.D., Key B., Westerfield M., and Parton R.G. Zebrafish as a model for caveolin-associated muscle disease; caveolin-3 is required for myofibril organization and muscle cell patterning. Hum. Mol. Genet. 14 (2005) 1727-1743
11. Smythe G.M., Eby J.C., Disatnik M.H., and Rando T.A. A caveolin-3 mutant that causes limb girdle muscular dystrophy type 1C disrupts Src localization and activity and induces apoptosis in skeletal myotubes. J. Cell Sci. 116 (2003) 4739-4749
12. Smythe G.M., and Rando T.A. Altered caveolin-3 expression disrupts PI(3) kinase signaling leading to death of cultured muscle cells. Exp. Cell Res. 312 (2006) 2816-2825
13. Bodine S.C., Stitt T.N., Gonzalez M., Kline W.O., Stover G.L., Bauerlein R., Zlotchenko E., Scrimgeour A., Lawrence J.C., Glass D.J., and Yancopoulos G.D. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 3 (2001) 1014-1019
14. Peng X.D., Xu P.Z., Chen M.L., Hahn-Windgassen A., Skeen J., Jacobs J., Sundararajan D., Chen W.S., Crawford S.E., Coleman K.G., and Hay N. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev. 17 (2003) 1352-1365
15. Lai K.M., Gonzalez M., Poueymirou W.T., Kline W.O., Na E., Zlotchenko E., Stitt T.N., Economides A.N., Yancopoulos G.D., and Glass D.J. Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. Mol. Cell Biol. 24 (2004) 9295-9304
16. Iezzi S., Di Padova M., Serra C., Caretti G., Simone C., Maklan E., Minetti G., Zhao P., Hoffman E.P., Puri P.L., and Sartorelli V. Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell. 6 (2004) 673-684
17. Horsley V., Jansen K.M., Mills S.T., and Pavlath G.K. IL-4 acts as a myoblast recruitment factor during mammalian muscle growth. Cell 113 (2003) 483-494
18. Peter A.K., and Crosbie R.H. Hypertrophic response of Duchenne and limb-girdle muscular dystrophies is associated with activation of Akt pathway. Exp. Cell Res. 312 (2006) 2580-2591
19. Bodine S.C., Latres E., Baumhueter S., Lai V.K., Nunez L., Clarke B.A., Poueymirou F.J., Panaro E.Na.K., Dharmarajan Z.Q., Pan D.M., Valenzuela T.M., DeChiara W.T., Stitt T.N., Yancopoulos G.D., and Glass D.J. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294 (2001) 1704-1708
20. Gomes M.D., Lecker S.H., Jagoe R.T., Navon A., and Goldberg A.L. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. USA 98 (2001) 14440-14445
21. Lecker S.H., Jagoe R.T., Gilbert A., Gomes M., Baracos V., Bailey J., Price S.R., Mitch W.E., and Goldberg A.L. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18 (2004) 39-51
22. Sandri M., Sandri C., Gilbert A., Skurk C., Calabria E., Picard A., Walsh K., Schiaffino S., Lecker S.H., and Goldberg A.L. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117 (2004) 399-412
23. McPherron A.C., Lawler A.M., and Lee S.J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387 (1997) 83-90
24. McFarlane C., Plummer E., Thomas M., Hennebry A., Ashby M., Ling N., Smith H., Sharma M., and Kambadur R. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. J. Cell Physiol. 209 (2006) 501-514